Brits denied new targeted bowel cancer drugs

	Tweet

Despite the fact that bowel cancer is the third most common form of the disease in Britain and kills 16,000 people every year, the government watchdog on drugs the National Institute for Health and Clinical Excellence (NICE) has sparked a bitter controversy by refusing to provide two bowel cancer drugs on the National Health Service (NHS) to cancer patients.

Their grounds for refusal are that the two new targeted therapies for bowel cancer, Avastin and Erbitux, are not cost effective.

Both Avastin and Erbitux are widely available in the United States and much of Europe.

NICE is the body responsible for deciding which medicines are worth using on the state health service in England and Wales, and although neither drug is a cure for bowel cancer, the treatments have been shown in clinical trials to extend life expectancy by around four to five months in some patients.

Avastin, known generically as bevacizumab, works by starving tumours of blood supply, while Erbitux, or cetuximab, stops the proliferation of cancer cells.

Cancer charities are up in arms and are planning to challenge the ruling, saying it is a scandal and a backward step and warning that thousands of patients will die early as a result.

Bowel Cancer UK, says the decision is further proof that the NHS is simply not working for bowel cancer patients and needs a full and comprehensive review.

The organisation points out a £10 billion overspend on controversial IT programmes by the government, yet patients are denied treatments that can help them live longer and better lives.

Nice has said neither drug represents a good use of scarce NHS resources, and though bevacizumab does show some increased benefit over standard treatment, the appraisal committee was not persuaded that it was cost- effective in the treatment of metastatic colorectal cancer.

NICE says the average cost of treating a patient with Avastin was around £16,800 pounds, while Erbitux would cost some £11,700 pounds, based on doses given during clinical studies.

Avastin was discovered by U.S. biotech group Genentech Inc. and is marketed in Europe by Switzerland’s Roche Holding. Erbitux, from U.S. firm ImClone Systems Inc., is sold in Europe by Germany’s Merck KGaA.

RELATED STORIES:
Van Andel Research Institute Finding Could Lead to Reduced Side Effects in Anti-Cancer Antibiotics   Tumor mechanism identified   Cancer cells accelerate aging and inflammation in the body to drive tumor growth   UCR scientists identify pomegranate juice components that could stop cancer from spreading   China’s “cancer villages” bear witness to economic boom   Compound that blocks sugar pathway slows cancer cell growth   How Eating Red Meat Can Spur Cancer Progression   Personality not linked to cancer risk or prognosis   Formula may help predict personal melanoma risk   Scientists Share Data about Malignant Hyperthermia   Three ‘Targeted’ Cancer Drugs Raise Risk of Fatal Side Effects   Sensitizing tumor response to cancer therapy   UK cancer survival rates, spending lag Europe   Antibody signal may redirect inflammation to fuel cancer   Broccoli, cauliflower and cabbage help repair damaged DNA   Insight into the anti-cancer effect of exercise   New Study Begins for Kids With High-Risk Cancer   Study shows gene positions may aid cancer diagnosis   Cancer Prevention News Tips   Obesity drug ‘may fight cancer’   Therapeutic gene suspected to cause cancer   Targeting cholesterol may help slow glioblastoma

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]